The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations

Somaia Mohamed¹, Gary R Johnson², Julia E Vertrees³, Peter D Guarino⁴, Kimberly Weingart⁵, Ilanit Tal Young⁵, Jean Yoon⁶, Theresa C Gleason⁷, Katherine A Kirkwood², Amy M Kilbourne⁸, Martha Gerrity⁹, Stephen Marder¹⁰, Kousick Biswas¹¹, Paul Hicks¹², Lori L Davis¹³, Peijun Chen¹⁴, AlexandraMary Kelada⁵, Grant D Huang¹⁵, David D Lawrence², Mary LeGwin², Sidney Zisook⁵

Affiliations

¹ VA VISN 1 New England Mental Illness Research,Education and Clinical Center, Veterans Health Administration, West Haven, CT and Yale University School of Medicine, 950 Campbell Ave., West Haven, CT 06516, USA. Electronic address: Somaia.Mohamed@va.gov.
² VA Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, USA.
³ VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, New Mexico VA Healthcare System, Albuquerque, NM, USA.
⁴ VA Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, USA; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁵ VA San Diego Healthcare System and University of California, San Diego, CA, USA.
⁶ Health Economics Resource Center (HERC), VA Palo Alto, Menlo Park, CA, USA.
⁷ Department of Veterans Affairs, Office of Research and Development, Washington, DC, USA.
⁸ Department of Veterans Affairs, Office of Research and Development, Washington, DC, USA; Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.
⁹ Portland VA Healthcare System, Portland, OR, USA.
¹⁰ VA Desert Pacific Mental Illness Research, Education, and Clinical Center and Semel Institute for Neuroscience at UCLA, Los Angeles, CA, USA.
¹¹ VA Cooperative Studies Program Coordinating Center, VA Maryland Healthcare Systems, Perry Point, MD, USA.
¹² Central Texas Veterans Healthcare System and Department of Psychiatry and Behavioral Science, Texas A&M Health Science Center College of Medicine, Temple, TX, USA.
¹³ Tuscaloosa VA Medical Center, Tuscaloosa, AL and University of Alabama School of Medicine, USA.
¹⁴ Louis Stokes VA Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA.
¹⁵ Cooperative Studies Program Central Office, Department of Veterans Affairs Office of Research & Development, Washington, DC, USA.

PMID: 26279130
DOI: 10.1016/j.psychres.2015.08.005

Randomized Controlled Trial

The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations

Somaia Mohamed et al. Psychiatry Res. 2015.

. 2015 Oct 30;229(3):760-70.

doi: 10.1016/j.psychres.2015.08.005. Epub 2015 Aug 6.

Authors

Affiliations

¹ VA VISN 1 New England Mental Illness Research,Education and Clinical Center, Veterans Health Administration, West Haven, CT and Yale University School of Medicine, 950 Campbell Ave., West Haven, CT 06516, USA. Electronic address: Somaia.Mohamed@va.gov.
² VA Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, USA.
³ VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, New Mexico VA Healthcare System, Albuquerque, NM, USA.
⁴ VA Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven, CT, USA; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁵ VA San Diego Healthcare System and University of California, San Diego, CA, USA.
⁶ Health Economics Resource Center (HERC), VA Palo Alto, Menlo Park, CA, USA.
⁷ Department of Veterans Affairs, Office of Research and Development, Washington, DC, USA.
⁸ Department of Veterans Affairs, Office of Research and Development, Washington, DC, USA; Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.
⁹ Portland VA Healthcare System, Portland, OR, USA.
¹⁰ VA Desert Pacific Mental Illness Research, Education, and Clinical Center and Semel Institute for Neuroscience at UCLA, Los Angeles, CA, USA.
¹¹ VA Cooperative Studies Program Coordinating Center, VA Maryland Healthcare Systems, Perry Point, MD, USA.
¹² Central Texas Veterans Healthcare System and Department of Psychiatry and Behavioral Science, Texas A&M Health Science Center College of Medicine, Temple, TX, USA.
¹³ Tuscaloosa VA Medical Center, Tuscaloosa, AL and University of Alabama School of Medicine, USA.
¹⁴ Louis Stokes VA Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA.
¹⁵ Cooperative Studies Program Central Office, Department of Veterans Affairs Office of Research & Development, Washington, DC, USA.

PMID: 26279130
DOI: 10.1016/j.psychres.2015.08.005

Abstract

Because two-thirds of patients with Major Depressive Disorder do not achieve remission with their first antidepressant, we designed a trial of three "next-step" strategies: switching to another antidepressant (bupropion-SR) or augmenting the current antidepressant with either another antidepressant (bupropion-SR) or with an atypical antipsychotic (aripiprazole). The study will compare 12-week remission rates and, among those who have at least a partial response, relapse rates for up to 6 months of additional treatment. We review seven key efficacy/effectiveness design decisions in this mixed "efficacy-effectiveness" trial.

Keywords: Antidepressants; Antipsychotics; Major depression; Methodology; Study design; Treatment resistance.

PubMed Disclaimer

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations

Affiliations

The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials